Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
作者信息
von Itzstein Mitchell S, Gonugunta Amrit S, Wang Yiqing, Sheffield Thomas, Lu Rong, Ali Sadia, Fattah Farjana J, Xie Donglu, Cai Jennifer, Xie Yang, Gerber David E
机构信息
Department of Internal Medicine, Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd., Mail Code 8852, Dallas, TX, 75390-8852, USA.
Harold C. Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA.
出版信息
Cancer Immunol Immunother. 2022 Sep;71(9):2183-2184. doi: 10.1007/s00262-022-03218-0.
Abstract
摘要
相似文献
1
Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.对《免疫检查点抑制剂治疗患者中既往存在的和治疗后出现的甲状腺功能障碍的不同预后影响》的更正
Cancer Immunol Immunother. 2022 Sep;71(9):2183-2184. doi: 10.1007/s00262-022-03218-0.
2
Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.免疫检查点抑制剂引起的甲状腺功能障碍与较高的体重指数有关。
J Clin Endocrinol Metab. 2020 Oct 1;105(10). doi: 10.1210/clinem/dgaa458.
3
Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors.甲状腺形态变化作为免疫检查点抑制剂治疗肺癌疗效的新影像学标志物。
Acta Radiol. 2021 Jan;62(1):42-50. doi: 10.1177/0284185120916197. Epub 2020 Apr 8.
4
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.在使用细胞毒性T淋巴细胞抗原4和程序性死亡受体蛋白1抑制剂治疗黑色素瘤后出现的甲状腺异常。
Clin Endocrinol (Oxf). 2017 Apr;86(4):614-620. doi: 10.1111/cen.13297. Epub 2017 Jan 27.
5
Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review.免疫检查点抑制剂所致甲状腺功能障碍：综述
Int J Gen Med. 2020 Nov 4;13:1003-1009. doi: 10.2147/IJGM.S261433. eCollection 2020.
6
Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients.免疫检查点抑制剂引起的甲状腺功能障碍的类型与癌症患者预后的关系。
BMC Endocr Disord. 2022 Apr 4;22(1):89. doi: 10.1186/s12902-022-01004-8.
7
Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors.免疫检查点抑制剂所致持续性与暂时性甲状腺功能障碍的不同临床特征及预后
Endocr J. 2021 Feb 28;68(2):231-241. doi: 10.1507/endocrj.EJ20-0371. Epub 2020 Oct 3.
8
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.PD-L1 抑制剂诱导的甲状腺炎与癌症患者的总体生存改善相关。
Thyroid. 2020 Feb;30(2):177-184. doi: 10.1089/thy.2019.0250. Epub 2020 Jan 9.
9
Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.免疫检查点抑制剂诱导的甲状腺功能障碍的临床特征及其影响：来自一家转诊机构的长期前瞻性研究。
J Endocrinol Invest. 2018 May;41(5):549-556. doi: 10.1007/s40618-017-0772-1. Epub 2017 Oct 17.
10
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction.检查点抑制剂诱导的甲状腺功能障碍的两种不同临床模式。
Endocr Connect. 2020 Apr;9(4):318-325. doi: 10.1530/EC-19-0473.
引用本文的文献
1
Thyroid disorders induced by immune checkpoint inhibitors.免疫检查点抑制剂引起的甲状腺疾病。
Endocrine. 2024 Jul;85(1):67-79. doi: 10.1007/s12020-024-03718-2. Epub 2024 Feb 12.
Zotero 插件